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Abstract  
Genetics has proven to be a powerful approach in neurodegenerative diseases research, 
resulting in the identification of numerous causal and risk variants. Previously, we introduced 
the NeuroX Illumina genotyping array, a fast and efficient genotyping platform designed for the 
investigation of genetic variation in neurodegenerative diseases. Here, we present its updated 
version, named NeuroChip. The NeuroChip is a low cost, custom-designed array containing a 
tagging variant backbone of about 306,670 variants complemented with a manually curated 
custom content comprised of 179,467 variants implicated in diverse neurological diseases, 
including Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, amyotrophic lateral 
sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration 
and multiple system atrophy. The tagging backbone was chosen because of the low cost and 
good genome-wide resolution; the custom content can be combined with other backbones, like 
population or drug development arrays. Using the NeuroChip, we can accurately identify rare 
variants and impute over 5.3 million common SNPs from the latest release of the Haplotype 
Reference Consortium. In summary, we describe the design and usage of the NeuroChip array, 
and show its capability for detecting rare pathogenic variants in numerous neurodegenerative 
diseases. The NeuroChip has a more comprehensive and improved content, which makes it a 
reliable, high-throughput, cost-effective screening tool for genetic research and molecular 
diagnostics in neurodegenerative diseases. 
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1. Introduction 
Neurodegenerative diseases are a major burden to the aging world population and currently 
these diseases are incurable and irreversible. Common and rare genetic alterations in many 
genes have been identified as disease-causing or contributing to the development of 
neurodegeneration (Naj et al., 2017, Singleton and Hardy, 2016). To date, there are four main 
uses of genetics: 1) to confirm a clinical diagnosis by identifying a causal mutation, 2) to identify 
risk variants and disease modifiers that influence risk for disease, 3) to increase knowledge of 
the molecular pathobiology of disease in the hopes of identifying therapeutic targets, and 4) to 
improve patient selection for pathway-specific clinical trial design. A reliable, high-throughput 
and cost-effective platform that can rapidly conduct these functions could therefore be 
immensely valuable to the field.  
Previously, we presented the NeuroX array, which was a collaborative effort with the objective 
of designing a genotyping platform that would allow rapid genetic characterization of samples 
in the context of genetic mutations and risk factors associated with common 
neurodegenerative diseases (Nalls et al., 2015). This was an exonic array (or exome chip) based 
on the Infinium HumanExome Beadchip v1.1 containing 242,901 exome-focused variants as 
well as 24,706 custom variants focusing on neurological diseases. The NeuroX array has already 
been successfully used in dozens of studies (Barber et al., 2017, Carrasquillo et al., 2016, Ghani 
et al., 2015, Nalls et al., 2016, Rosenthal et al., 2016). However, due to the backbone’s focus on 
rare exonic variation, common non-exonic variants were largely missed, resulting in a modest 
genome-wide resolution and only partial capture of the known low frequency exonic variation. 
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Additionally, the number of genotype-phenotype associations and pathogenic variants keeps 
expanding, so there was a continued need for updating this useful platform. 
Here, we report on an updated version of NeuroX, named NeuroChip. The NeuroChip backbone 
is based on a genome-wide genotyping array (Infinium HumanCore-24 v1.0) containing 306,670 
tagging variants and a custom content that has been updated and extended with 
neurodegenerative disease-related custom content consisting of 179,467 variants. This 
backbone was chosen because of the low cost and good genome-wide resolution. This 
backbone is flexible and other arrays can be used with this custom content, such as population 
or drug development arrays (Infinium Multi-Ethnic, Infinium DrugDev). The NeuroChip allows to 
accurately identify rare neurodegenerative candidate variants and impute over 5.3 million 
common variants. Its approximate cost of ~$40 per sample is a fraction of the price of next-
generation whole exome or whole genome sequencing, and therefore provides a valuable, 
high-throughput screening tool for loci and variants implicated in neurodegenerative diseases. 
Further, this array can be used as a tool to prioritize samples for more expensive genome 
sequencing approaches.  
 
2. Methods 
2.1 NeuroChip array design 
The backbone of the array, the Infinium HumanCore-24 v1.0, contains 306,670 highly 
informative tagging SNPs which can be used for high-throughput and high-quality imputation of 
genome-wide variants across diverse populations (Illumina). In addition, the chip contains 
179,467 custom disease-associated variants (Table 1) covering neurodegenerative diseases 
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including: Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD), 
frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). The custom-
content has been curated by members of the International Parkinson’s Disease Genomics 
Consortium (IPDGC) and the Comprehensive Unbiased Risk factor Assessment for Genetics and 
Environment in Parkinson disease (COURAGE-PD) consortium to include common variants and 
rare mutations implicated in neurological diseases as reported in the Human Gene Mutation 
Database (HGMD Professional 2016.4, QIAGEN), the NHGRI GWAS Catalog 
(www.ebi.ac.uk/gwas/), the Online Mendelian Inheritance in Man (OMIM) database 
(www.ncbi.nlm.nih.gov/omim/), the Parkinson’s Disease Mutation Database (www.molgen.vib-
ua.be/PDMutDB), the Alzheimer’s Disease and Frontotemporal Dementia Database 
(www.molgen.ua.ac.be/admutations/), and based on literature review as well as own data; 
particularly in the latter case, collaborators submitted variants that were identified in multiple 
ongoing (or completed) unpublished projects, including variants from genome-wide association 
(GWA), whole exome, whole genome, targeted sequencing studies and systems biology studies. 
See Supplementary Table 1 for the complete content of the NeuroChip array.  
 
2.2 NeuroChip array genotyping  
We genotyped a cohort of 273 controls as per the manufacturer's instructions (Illumina) to 
generate pilot NeuroChip data. These samples have been collected by the North American Brain 
Expression Consortium (NABEC) and described elsewhere (Hernandez et al., 2012). In total, 183 
males and 90 females were included. All samples were obtained from North American brain 
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banks; included subjects reported European ancestry and had no reported neurological disease. 
To assess the reproducibility of the NeuroChip, we genotyped 15 samples twice in separate 
experiments.  
Raw data files were imported into GenomeStudio (version 2.0, Illumina). For initial quality 
control, we confirmed accurate, high quality genotyping using a call rate threshold of > 95%. 
We reclustered the samples using a GenCall threshold of 0.15 and recalled all variants. The 
genotyping cluster file based on ~3,500 individuals of ongoing projects is available in the 
Supplementary Materials (Supplementary File 1). The mean call rate post-reclustering was 
0.992 (range: 0.954-0.995). The data were exported from GenomeStudio using the Illumina-to-
PLINK module 2.1.4 and imported into PLINK (version 1.90) (Chang et al., 2015). Next, we 
checked individuals for discrepancies between reported sex and genotypic sex, cryptic 
relatedness (PIHAT <0.05), and heterogeneity contamination, and found that no samples failed 
this quality control step.  
 
2.3 NeuroChip content annotation 
Annotation of the NeuroChip content was performed using ANNOVAR (Wang et al., 2010). For 
each variant, a gene-based annotation, in silico impact scores, and frequencies from public 
databases were obtained. To predict the impact scores, the following algorithms were used: 
SIFT (Kumar et al., 2009), Polyphen-2 (Adzhubei et al., 2010), and CADD (Kircher et al., 2014). 
Population frequencies were obtained from the Exome Aggregation Consortium (version 0.3.1) 
(http://exac.broadinstitute.org/) containing 60,706 individuals. Additionally, all variants were 
investigated for their presence in the Human Gene Mutation Database (HGMD, accessed 20 
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December 2016). Variants associated with a common neurodegenerative syndrome (AD, ALS, 
FTD and PD) were manually curated and are summarized in Supplementary Table 2.  
 
2.4 NeuroChip content imputation  
After confirming high-quality genotyping (call rate >95%) and European ancestry in all 
individuals (based on 1000Genomes clustering) (Genomes Project et al., 2015), we performed 
imputation using the Michigan imputation server, according to established guidelines 
(https://imputationserver.sph.umich.edu) (Das et al., 2016). In brief, genotypes were prepared 
for imputation using provided scripts (HRC-1000G-check-bim.pl), which compares variant ID, 
strand, and allele frequencies to the haplotype reference panel (HRC version r1.1, April 2016) 
(McCarthy et al., 2016). A total of 332,015 autosomal SNPs were submitted to the Imputation 
Server using ShapeIT (v2.r790).  
 
2.5 APOE allele genotyping 
To determine the accuracy of APOE allele predictions, we performed Taqman genotyping of 
two nonsynonymous APOE SNPs (rs7412 and rs429358) on an Applied Biosystems ViiA 7 Real-
Time PCR System using an established protocol (Federoff et al., 2012). 272 out of 273 control 
samples had sufficient DNA for genotyping. Allelic discrimination was conducted using 
QuantStudio software (version 1.3, Thermo Fisher Scientific, Carlsbad, CA, USA). Taqman 
genotype results were then compared to the corresponding results for the same SNPs 
generated using the NeuroChip. Given the importance of APOE, NeuroChip was designed so 
that rs7412 is genotyped by four separate probes (three of which performed well: rs7412, seq-
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rs7412-B1, seq-rs7412-B3). Similarly, rs429358 was genotyped by five separate bead probes 
(two of which performed well: seq-rs429358-T2, seq-rs429358-T3). This redundancy ensures 
accurate APOE genotyping by the NeuroChip platform.  
 
3. Results 
3.1 NeuroChip content overview 
In total, the NeuroChip array contains 473,442 autosomal variants, 11,840 sex chromosomal 
variants, and 160 mitochondrial variants. Additionally, 16,274 NeuroChip variants detect small 
insertions or deletions (Table 1). The overlap between NeuroX and NeuroChip is small (n= 
19,289 variants) due to the difference in the design of the backbone; the NeuroX array is 
focused on exonic content, whereas the NeuroChip is focused on genome wide tagging content.  
 
3.2 NeuroChip pathogenic variant content 
In total, the NeuroChip harbors 8,086 disease-associated variants that are included in HGMD, a 
professionally curated database of published genetic variants that have been linked to inherited 
human diseases (neurological and non-neurological). The NeuroChip HGMD content includes 
1,233 variants (1,202 SNPs and 31 indels) linked to common neurodegenerative syndromes (see 
Supplementary Figure 1 for a comparison between NeuroX and NeuroChip). In this content, 
after manually curation, 601 variants are associated with ALS or FTD, 348 with PD, and 284 with 
AD. Figure 1 shows the number of disease-associated variants per gene covered in common 
neurodegenerative syndromes based on the HGMD database content. Detailed, manually 
curated and annotated variant lists for the abovementioned neurodegenerative disease 
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categories are documented in Supplementary Table 2. These annotated lists can be used as 
filters to quickly screen for known mutations and risk variants. 
 
3.3 NeuroChip genotyping results 
Genotyping reproducibility 
Of the 15 technical replicates, all samples yielded high quality, reproducible genotyping results. 
The mean concordance rate per technical replicate was 0.9996 (range=0.9991-0.9999); on 
average, 190 variants (range=27-435) differed per technical replicate (0.04% of the total 
included variants on the array). Across the 15 technical replicates, 1,978 unique variants were 
discordant, of which 749 (37.9%) were from the backbone and 1,229 (62.1%) were from the 
custom content (Supplementary Table 3). 
 
Imputation 
Imputation of autosomal variants was performed on a series of 273 European descent 
individuals using the haplotype reference panel (McCarthy et al., 2016) containing 39,235,157 
variants, all with an estimated minor allele count of >= 5 in 32,488 individuals. Initial pre-
imputation filtering of the NeuroChip data (including removing duplicates and non-overlapping 
variants, switch strands, and updating position) resulted in 332,015 variants. After imputation, 
11,879,345 variants were obtained with an imputation R
2
 of > 0.30. Filtering based on MAF > 
0.05, Hardy-Weinberg Equilibrium p-value of > 1e-6 resulted in 5,316,028 variants. In this 
imputed dataset, we successfully identified 22 of 26 PD risk alleles and 19 of the 21 AD GWA 
SNPs (Lambert et al., 2013, Nalls et al., 2014).  
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Genotype accuracy 
GenTrain scores were calculated for all NeuroChip variants using GenomeStudio (version 2, 
lllumina). The GenTrain score is a statistical score based on the shapes of the different allelic 
clusters and their relative distance to each other (Illumina). Typically, GenTrain scores > 0.7 are 
considered high quality genotypes. Previously, GenTrain scores of the NeuroX showed that 
genotyping quality in the custom content was lower compared to the backbone (Nalls et al., 
2015). However, preliminary NeuroChip data from several ongoing projects (based on ~3,500 
individuals) reveals that the backbone and the custom content have a high comparable average 
score (0.819 and 0.820, respectively), indicating high genotyping accuracy (Supplementary 
Figures 2 & 3). 
 
Validation of APOE genotyping 
APOE alleles are important genetic risk factors for both AD and LBD, but genotyping of this 
region is complicated by high GC content (Singleton et al., 2002, Strittmatter and Roses, 1996). 
For this reason, we chose to validate the accuracy of APOE allele genotyping by comparing 
Taqman results with genotype predictions from the NeuroChip (Supplementary Table 4). 
Taqman genotyping for rs7412 and rs429358 was successful in all 272 samples. NeuroChip 
genotyping for both SNPs was successful in 265 out of these 272 controls. Five samples were 
discordant for APOE allele genotyping between Taqman and NeuroChip due to relatively low 
quality genotype calls in either the Taqman assay or the NeuroChip, representing 1.9% of our 
test cohort (n = 265 samples). Overall, the performance of the NeuroChip for APOE genotyping 
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13 
was remarkable improved compared to the original NeuroX platform, which was unable to 
reliably detect rs7412 and rs429358 genotypes (Ghani et al., 2015, Nalls et al., 2015).  
 
4. Discussion 
The main goal was to develop a genotyping array that allows a rapid, high-throughput 
identification of common and rare single nucleotide variants in the human genome. Affordable 
screening of large cohorts for disease-associated variants allows for testing of polygenic 
inheritance that could explain the diversity of clinical and pathological characteristics of 
neurodegenerative diseases. The NeuroChip is estimated to cost ~ $40/sample, which is 
currently less than ~ 10% and ~ 5% of the cost of whole exome sequencing and whole genome 
sequencing, respectively. 
We have designed, implemented, and validated the NeuroChip array platform for high 
throughput genotyping. However, it is important to recognize the limitations of this approach. 
Like all genotyping arrays, NeuroChip does not detect novel sequence changes. It is also not 
possible to genotype variants in complex genomic regions (e.g. due to pseudogenes) or to 
identify repeat expansions due to the difficulty in designing reliable probes. Nevertheless, every 
effort was made to improve genotyping calling in NeuroChip. For example, it was recognized 
that the APOE locus performed poorly on the original NeuroX platform (Ghani et al., 2015). 
Given the importance of this genomic region in neurodegeneration, the revised NeuroChip 
probe design included multiple probes for SNPs in this region. This led to reliable APOE allele 
calling with a concordance rate of 98.1% between NeuroChip and Taqman. 
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In conclusion, we describe the design and implementation of the NeuroChip array, which has a 
more comprehensive and improved content compared to NeuroX. This versatile genotyping 
platform provides the community with a novel tool that can be used in clinical and research 
settings. In a clinical setting, it is possible to rapidly screen patients for a large number of known 
pathogenic variants, and in a research setting cost-effective and high-throughput detection of 
common and rare variants provides opportunities to perform several large-scale analyses, 
including GWAS, burden tests and genetic risk scores calculations 
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Table 1. Differences between NeuroX and the NeuroChip.  
Variant Description NeuroX NeuroChip Comparison 
Total variants (pre-QC)  267,607 486,137 +218,530 
Backbone 242,901 306,670 +63,769 
Custom-content variants 24,706 179,467 +154,761 
Indels 200 16,259 +16,059 
Autosomal variants 261,477 473,442 +211,965 
Coding variants 226,104 88,560 -137,544 
Sex chromosomal variants 5,906 11,840 +5,934 
Mitochondrial variants 219 160 -59 
Variants with MAF < 0.05 219,093 227,448 +8,355 
Variants with MAF < 0.001 179,500 154,953 -24,547 
MAF = minor allele frequency 
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Figure 1. 
 
 
 
Overview of the number of HGMD disease associated variants that are present on the NeuroChip. AD = Alzheimer’s disease, ALS = 
amyotrophic lateral sclerosis, FTD = frontotemporal dementia, and PD = Parkinson’s disease 
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Highlights 
• NeuroChip is a genotyping chip for rapid screening of variants implicated in neurological 
disease  
• This affordable and versatile array allows robust identification of common and rare 
variants 
• NeuroChip is a high-throughput screening tool for genetic research and molecular 
diagnostics 
• Here, we describe the design, implementation and validation of the NeuroChip 
